Evidence map›Paper›PMID 27600388›Full record

ArticleJournal of endocrinological investigation2017

Is peritoneal dialysis causing a measurable burden of inflammatory and endothelial injury on top of metabolic syndrome?

M Miler, N Nikolac, D Segulja, S Kackov Maslac, I Celap, K Altabas, S Sefer, A M Simundic

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. New-Onset Diabetes Mellitus in Peritoneal Dialysis and Hemodialysis Patients: Frequency, Risk Factors, and Prognosis-A Review.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2019
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M MilerUniversity Department of Chemistry, Sestre Milosrdnice Medical School University Hospital, Zagreb, Croatia. marijana.miler@gmail.com.
N NikolacUniversity Department of Chemistry, Sestre Milosrdnice Medical School University Hospital, Zagreb, Croatia.
D SeguljaDepartment of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
S Kackov MaslacMedical Biochemistry Laboratory, Policlinic Bonifarm, Zagreb, Croatia.
I CelapUniversity Department of Chemistry, Sestre Milosrdnice Medical School University Hospital, Zagreb, Croatia.
K AltabasDepartment of Nephrology and Dialysis, Medical School University Hospital Sestre Milosrdnice, Zagreb, Croatia.
S SeferDepartment of Nephrology and Dialysis, Medical School University Hospital Sestre Milosrdnice, Zagreb, Croatia.
A M SimundicDepartment of Medical Laboratory Diagnostics, University Hospital "Sveti Duh", Zagreb, Croatia.
Sisters of Charity Hospital · HRUniversity Hospital Centre Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLow-grade chronic inflammation is present in patients on peritoneal dialysis (PD) and in metabolic syndrome (MS). Due to possible greater endothelial changes in dialyzed patients, inflammatory response and oxidative stress are probably stronger in patients on PD. The objective of the study was to investigate possible in between adipokines, inflammatory, endothelial and oxidative stress markers between MS patients and patients on PD.

methodsConcentrations of adipokines (leptin, resistin), inflammatory markers [interleukin-6 (IL-6), soluble tumor necrosis factor alpha receptor (sTNF-R), myeloperoxidase (MPO), monocyte chemoattractant protein 1 (MCP-1)] and endothelial markers [soluble intracellular adhesion molecule-1 (sICAM-1), soluble CD40 ligand (sCD40L)] were determined in 55 MS patients and 18 patients on PD, with flow cytometry, and visfatin concentration was measured with ELISA. Routine biochemistry parameters were measured on Beckman Coulter AU2700 analyzer.

resultsPatients on PD have significantly higher concentration of: CRP [6.5 (3.7-12.1) versus 2.6 (1.3-4.0) mg/L, P < 0.001], IL-6 [13.83 (8.48-31.31) versus 2.05 (0.67-4.11) pg/mL, P < 0.001], MCP-1 [2172.28 (1563.84-2922.77) versus 1353.58 (1166.33-1961.70) pg/mL, P = 0.023], sTNF-R [18.25 (12.81-25.22) versus 1.23 (0.89-1.43) ng/mL, P < 0.001] and sICAM-1 [830.03 (599.21-967.02) versus 463.85 (315.25-751.71) ng/mL, P = 0.006] than subjects with MS. MS patients have higher concentrations of MPO [175.47 (120.15-231.67) versus 101.76 (53.55-186.06) ng/mL, P = 0.016] and visfatin [1.5 (0.9-2.3) versus 0.9 (0.6-1.6) ng/mL, P = 0.013].

conclusionIn patients on PD, inflammatory reaction is higher than in patients with MS. On the contrary, patients with MS have stronger oxidative stress response and adipose tissue activity caused probably by the chronic low level of inflammation and underlying metabolic disorders.

Indexed as

Oxidative StressAgedAged, 80 and overBiomarkersBody Mass IndexCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansInflammationInflammation MediatorsMaleMetabolic SyndromeMiddle AgedPeritoneal DialysisBiomarkersInflammation MediatorsAdipokinesEndothelial impairmentInflammationMetabolic syndromeOxidative stressPeritoneal dialysis

Identifiers

PMID27600388
OpenAlexW2520716510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.